We found that advanced heart failure and transplant cardiologists are few in number and unevenly distributed across the United States, leaving many regions with limited access to specialized care. https://t.co/lUsu9Mhbw3 #ACC26@HarringtonHVI
Congestion drives HF decompensation. Can an implantable IVC sensor safely guide care for 12 months?
In FUTURE-HF, ambulatory IVC-guided care was safe, accurate, and actionable, with improved congestion and fewer HF events. Supports a pivotal trial.
https://t.co/LcbDVZfTV1
@AndrewJSauer@drjohnm AHF cards actually spend a significant amount of time interacting with community. Most AHF programs have outreach clinics , CS transfer protocols and inpatient availability at there community based hospitals in there systems. we don’t sit in ivory towers waiting for pts :-)
⚖️ Want to review the economic value of HF therapies?
Find that here:
📖 Read the report ➡️ https://t.co/z0cObHYV3M…
📺 Watch the highlights ➡️ https://t.co/5Xqth9vH33
Here are all AHFTC fellowship programs that offered spots in last 5 years, and # of fellows they matched. 13 programs trained 50% of fellows. #HFSA2025 Skewed uneven distribution. Mega centers train most of the field. Insufficient exposure to community and rural needs. Worrisome.
🚧 The total direct costs for individuals with HF are estimated to be $227 billion in the US
HF-related costs are projected to grow significantly:
🚨 total direct medical costs for individuals with HF could rise to $858 billion by 2050
🎯 prioritize HF prevention and Rx
ECMO is increasingly used a bridge to transplant. In this study of the UNOS database, use of #ECMO as a bridge to multiorgan #transplant was associated with increased 30 day mortality and decreased long-term survival @ElbertHeng@JW_MacArthur@StanfordCTSurg
🔗: https://t.co/De8EGrGrGC
3 out of 7 newly diagnosed ATTR-CM patients that I saw in 1 day didnt have ATTR-CM (2 on therapy). Just really tough to interpret PYP scans with blood pooling, and due to cavity size and shape they simply appeared as myocardial uptake to those reading them.
That is why we are running REVEAL (Evuzamitide in suspected cardiac amyloidosis). Cant afford making such mistakes.
https://t.co/zZM8kr5vda
#CardioTwitter #CVNuc
🧵Substrate-based vs. clinical VT ablation?!
In ischemic VT, should we pursue substrate mapping (sinus) vs. entrainment mapping (in VT) as ablation strategy?
VT recurrence at 12 months:
👉Substrate-based ablation 15%
👉 Clinical ablation 48%
VISTA Trial ⬇️
https://t.co/ONy5P7coQM
#Epeeps
@maybeadoc1983@drbennisahmed@mvaduganathan@JavedButler1 SCD ⬇️ in HFrEF RCTs where GDMT mandated by trial protocol
In clinical practice, SCD, progressive HF☠️, and all-cause ☠️ all ⬆️ since massive gaps in use and dosing in GDMT + rising HF incidence (w/o age adjustment)
Want to save 100,000 lives a year?
Apply GDMT by protocol
I am happy to announce today that I have started as Medical Director of Heart Failure of Robert Wood Johnson Barnabas Health (RWJBH) system. I would like to thank the leadership at RWJBH for giving me the honor and privilege to serve this region. My home state of New Jersey!
Excellent collaboration with the heart and kidney team @nyulangone to combine an LVAD implant with xeno kidney giving our patient a chance at life. Thank you to our patient and her family as well as our close collaborator
@KulpreetBarn https://t.co/CgMyYHeWWL
@ReyentovichHFMD@nyulangone This patient is very lucky to have the best team around her . No surprise she is doing so well. Congrats to the entire team @nyulangone
We are pleased to inform that our DOT-HM3 Trial results in partnership between IKEM and The Brigham Harvard just got online! Our results suggest a safety signal of Apixaban use with the HM3 up to a 6-months time point in stable LVAD patients. https://t.co/98omoxGm2W
@ShashankSinhaMD@NavinKapur4 @manreetkanwar @JHMontfort10@ReshadGaranMD@BurkhoffMd@JasonKatzMD Most advance centers are already doing this and add PA Catheter to guide therapy. What this trial really shows is that temporary MCS should be used early in the community and get these pts to local advance centers asap like left main or aortic dissection.
Amazing talk by Dr. @KulpreetBarn on evolving landscape of HFpEF @ACPNJ1 24
Main takeaways:
🌟SGLT2i: Only GDMT drug in HFpEF with class 2a recommendation. Use them!
🌟Consider screening HFpEF patients for amyloid.
#DAPAHFtrial
46 LVAD implants at DHLC this year. Special thanks to our entire team for all their hard work. Looking forward to helping more patients in 2024 with this therapy! Also very thankful to our referring providers for trusting us with their patients .